oxonic acid has been researched along with Cancer of Cervix in 11 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The other 36 received CRC at the same cisplatin and radiotherapy dosage as for CRSC." | 2.82 | Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial. ( Han, S; Li, Z; Lin, N; Mao, W, 2016) |
| "Irinotecan was administered intravenously over the course of 90 minutes on day 1, and S-1 was given orally in 2 divided doses from days 1 to 14 of a 21-day cycle." | 2.82 | Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy. ( Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016) |
| "This phase II study of S-1 in cervical cancer suggests a promising response rate and a contribution toward prolonging survival, with modest toxic effects." | 2.76 | Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. ( Hatae, M; Hirai, Y; Kamiura, S; Katsumata, N; Kokawa, K; Nishimura, R; Ochiai, K; Sugiyama, T, 2011) |
| "A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials." | 1.56 | Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series. ( Jiang, SN; Shang, YP; Wang, ZM; Xu, XJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, XJ | 1 |
| Wang, ZM | 1 |
| Shang, YP | 1 |
| Jiang, SN | 1 |
| Ma, L | 1 |
| Liu, JM | 1 |
| Zhang, J | 1 |
| Li, H | 1 |
| Aoki, Y | 1 |
| Ochiai, K | 2 |
| Lim, S | 1 |
| Aoki, D | 1 |
| Kamiura, S | 2 |
| Lin, H | 1 |
| Katsumata, N | 3 |
| Cha, SD | 1 |
| Kim, JH | 1 |
| Kim, BG | 1 |
| Hirashima, Y | 1 |
| Fujiwara, K | 1 |
| Kim, YT | 1 |
| Kim, SM | 1 |
| Chung, HH | 1 |
| Chang, TC | 1 |
| Kamura, T | 1 |
| Takizawa, K | 1 |
| Takeuchi, M | 1 |
| Kang, SB | 1 |
| Takatori, E | 1 |
| Shoji, T | 1 |
| Suga, Y | 1 |
| Niinuma, H | 1 |
| Miura, Y | 1 |
| Kaido, Y | 1 |
| Takada, A | 1 |
| Kagabu, M | 1 |
| Takeuchi, S | 1 |
| Sugiyama, T | 2 |
| Yunokawa, M | 2 |
| Yamamoto, H | 1 |
| Kodaira, M | 1 |
| Yonemori, K | 1 |
| Shimizu, C | 1 |
| Ando, M | 1 |
| Tamura, K | 1 |
| Fujiwara, Y | 1 |
| Li, Z | 1 |
| Mao, W | 1 |
| Lin, N | 1 |
| Han, S | 1 |
| Tanigawa, T | 1 |
| Matoda, M | 1 |
| Yamamoto, A | 1 |
| Nomura, H | 1 |
| Okamoto, S | 1 |
| Sakamoto, K | 1 |
| Kondo, E | 1 |
| Omatsu, K | 1 |
| Kato, K | 1 |
| Takeshima, N | 1 |
| Mabuchi, S | 1 |
| Yokoi, E | 1 |
| Owa, T | 1 |
| Kozasa, K | 1 |
| Yamashita, M | 1 |
| Kobayashi, E | 1 |
| Tomimatsu, T | 1 |
| Yoki, T | 1 |
| Tsutui, T | 1 |
| Kimura, T | 1 |
| Nagai, N | 1 |
| Komatsu, M | 1 |
| Shiroyama, Y | 1 |
| Hirata, E | 1 |
| Hirai, Y | 1 |
| Kokawa, K | 1 |
| Hatae, M | 1 |
| Nishimura, R | 1 |
| Takagi, K | 1 |
| Kougo, H | 1 |
| Aoyagi, Y | 1 |
| Yonehara, T | 1 |
| Minobe, S | 1 |
| Azuma, M | 1 |
| Yamaguchi, T | 1 |
7 trials available for oxonic acid and Cancer of Cervix
| Article | Year |
|---|---|
A pilot study of oral S-1 for treating heavily pretreated patients with advanced or recurrent cervical cancer among Chinese population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; China; Disease-Free Survival; Drug Combinations; Feasi | 2018 |
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 2018 |
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2013 |
Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Fem | 2016 |
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; | 2016 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2016 |
Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Human | 2011 |
4 other studies available for oxonic acid and Cancer of Cervix
| Article | Year |
|---|---|
Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged | 2020 |
A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 2014 |
Preclinical analysis of the antitumor efficacy of TS-1 using human uterine cervical cancer tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Mice; Oxonic Acid; Tega | 2008 |
[Remarkably reduced tumor marker SCC levels by combined chemotherapy of paclitaxel and S-1 in two cases of advanced cervical cancer].
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2008 |